157026-18-1

Basic information

• Product Name: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride
• Synonyms: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride;4-Bromo-2-nitro-6-(trifluoromethyl)aniline;4-Bromo-2-nitro-6-(trifluoromethyl)aniline, 2-Amino-5-bromo-3-(trifluoromethyl)nitrobenzene;4-bromo-2-nitro-6-(trifluoromethyl)Benzenamine
• CAS NO: 157026-18-1
• Molecular Formula: C₇H₄BrF₃N₂O₂
• Molecular Weight: 285.03
• Product Categories: Trifluoromethylbenzene serise
• Mol File: 157026-18-1.mol

Chemical Properties

• Boiling Point: 273.474 °C at 760 mmHg
• Flash Point: 119.193 °C
• Appearance: /Solid
• Density: 1.859 g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: -3.75±0.25(Predicted)
• CAS DataBase Reference: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride(157026-18-1)
• EPA Substance Registry System: 2-Amino-5-Bromo-3-Nitrobenzotrifluoride(157026-18-1)

Safety Data

• Hazardous Substances Data: 157026-18-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-5-Bromo-3-Nitrobenzotrifluoride is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique structure allows it to be a key component in the synthesis of drugs targeting specific receptors or enzymes in the human body.
Used in Chemical Research:
In the field of chemical research, 2-Amino-5-Bromo-3-Nitrobenzotrifluoride serves as a valuable compound for studying the effects of different functional groups on the properties and reactivity of organic molecules. It can be used to explore new reaction pathways and develop innovative synthetic methods.
Used in the Synthesis of TRPM8 Antagonists:
2-Amino-5-Bromo-3-Nitrobenzotrifluoride is used as a reagent for the preparation of 3-(5-arylbenzimidazol-2-yl)-1-oxa-2-azaspiro[4.5]decenes, which are transient receptor potential melastatin 8 (TRPM8) antagonists. These antagonists have potential applications in the treatment of painful conditions related to cold, providing a new avenue for pain management and relief.

InChI:InChI=1/C7H4BrF3N2O2/c8-3-1-4(7(9,10)11)6(12)5(2-3)13(14)15/h1-2H,12H2

Upstream product

• 105172-74-5 3-bromo-5-nitro-6-chlorobenzotrifluoride 
• 24821-17-8 2-Nitro-6-(trifluoromethyl)aniline 
• 1155800-52-4 N-(4-bromo-2-nitro-6-(trifluoromethyl)phenyl)-2,2,2-trifluoroacetamide 
• 29124-62-7 N-(4-bromo-2-trifluoromethyl-phenyl)-acetamide 
• 445-02-3 4-bromo-2-trifluoromethyl-aniline 
• 179062-00-1 N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide 

Downstream Products

• 157026-19-2 5-bromo-3-(trifluoromethyl)-1,2-benzenediamine 
• 1326310-54-6 4-cyclopropyl-2-nitro-6-(trifluoromethyl)aniline 
• 1326310-55-7 5-cyclopropyl-3-(trifluoromethyl)-1,2-benzenediamine 
• 1221349-87-6 1-oxa-2-aza-spiro[4.5]dec-2-ene-3-carboxylic acid (4-amino-5,2'-bis-trifluoromethyl-biphenyl-3-yl)-amide 
• 1276115-85-5 C₂₃H₂₁F₆N₃O₂ 
• 1276127-36-6 C₂₂H₂₁ClF₃N₃O₂ 
• 1276127-37-7 C₂₂H₂₁ClF₃N₃O₂ 
• 1276127-34-4 C₂₃H₂₁F₆N₃O₃ 
• 1276127-35-5 C₂₃H₂₁F₆N₃O₃ 
• 1276127-20-8 C₂₂H₂₁F₄N₃O₂ 
• 1276127-33-3 C₂₂H₂₁F₄N₃O₂ 
• 1259026-14-6 JNJ-41876666 
• 1221349-53-6 3-[7-trifluoromethyl-5-(2-trifluoromethylphenyl)-1H-benzimidazol-2-yl]-1-oxa-2-azaspiro[4.5]dec-2-ene 
• 1221349-68-3 3-[7-trifluoromethyl-5-(2-trifluoromethylphenyl)-1H-benzimidazol-2-yl]-1,8-dioxa-2-azaspiro[4.5]dec-2-ene 

Relevant articles and documents

BENZIMIDAZOLE ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein W1, W2, W3, R1/s

An efficient synthetic process for scale-up production of 4,5-diamino-2- (trifluoromethyl)benzonitrile and 5-bromo-3-(trifluoromethyl)benzene-1,2-diamine

Starting from 4-amino-2-(trifluoromethyl)benzonitrile (6), an efficient and nonchromatographic process was developed for multihundred gram production of 4,5-diamino-2-(trifluoromethyl)- benzonitrile (1) in 73% yield and 98 HPLC area% purity over four synthetic steps. The same synthetic strategy was applied to 4-bromo-2-(trifluoromethyl)aniline (7) that afforded 5-bromo-3- (trifluoromethyl)benzene-1,2-diamine (5) in 81% overall yield and 99% HPLC area% purity.

Substituted benzimidazoles

The invention relates to new substituted benzimidazoles of the general formula (I) STR1 in which R1 represents hydrogen, alkyl, alkoxy or optionally substituted aryl, R2 represents hydroxyl, cyano or in each case optionally substituted alkyl, alkenyl, alkinyl, alkoxy, alkenyloxy, alkinyloxy, alkylthio, amino, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, dialkoxyphosphonyl, (hetero)aryl, (hetero)arylcarbonyl, (hetero)aryloxycarbonyl, (hetero)arylcarbonyloxy or (hetero)arylaminocarbonylaminocarbonyloxy, and R3 represents fluoroalkyl, X1, X2, X3 and X4 independently of one another in each case represent hydrogen, halogen, cyano, nitro, in each case optionally substituted alkyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl or cycloalkyl, optionally substituted, fused dioxyalkylene, or represent hydroxycarbonyl, alkylcarbonyl, alkoxycarbonyl or cycloalkyloxycarbonyl, in each case optionally substituted amino or aminocarbonyl or in each case optionally substituted aryl, aryloxy, arylthio, arylsulphinyl, arylsulphonyl, arylsulphonyloxy, arylcarbonyl, aryloxycarbonyl, arylazo or arylthiomethylsulphonyl, but where at least one of the substituents X1, X2, X3 or X4 represents halogenoalkyl, with the exception of the chloromethyl radical, halogenoalkoxy, halogenoalkylthio, halogenoalkylsulphinyl, halogenoalkylsulphonyl or alkylsulphonyl, optionally substituted, fused dioxyalkylene, or represent hydroxycarbonyl, alkylcarbonyl, alkoxycarbonyl or cycloalkyloxycarbonyl, in each case optionally substituted amino or aminocarbonyl, or in each case optionally substituted aryl, arylthio, arylsulphinyl, arylsulphonyl, arylsulphonyloxy, arylcarbonyl, aryloxycarbonyl, arylazo or arylthiomethylsulphonyl, their preparation and use as pesticides, and intermediates for their preparation.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.